(Q36672691)

15 August 2017

1 reference

title

Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? (English)

1 reference

15 August 2017

1 reference

Hake CR

1

1 reference

15 August 2017

Graubert TA

series ordinal

2

1 reference

15 August 2017

Fenske TS

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

4 December 2006

1 reference

Bone Marrow Transplantation

15 August 2017

1 reference

15 August 2017

39

1 reference

15 August 2017

2

1 reference

15 August 2017

59-70

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705547

15 August 2017

0 references

cites work

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Second malignancies after Hodgkin's disease: the Munich experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Telomeres, stem cells, senescence, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Molecular genetics of human leukemias: new insights into therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Multiple primary cancers in families with Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Pharmacogenetics of alkylator-associated acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Association of CYP3A4 genotype with treatment-related leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Evaluation of therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Prognostic biomarkers in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Risk of leukemia following treatment for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Mutation of CEBPA in familial acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705547

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705547

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference